Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V221 (MMRV) Refrigerated vs Frozen in Healthy Children
NCT00092430Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2002
- Primary completion
- Jun 2003
- Modality
- Live Attenuated Vaccines
01
Overview
Phase 3, randomised trial of measles + mumps + rubella + varicella virus vaccine live in measles, mumps, rubella and 1 more (2 arms), sponsored by Merck & Co. Primary endpoint: Percent of patients demonstrating adequate antibody titers at 6 weeks. Started Sep 2002; status: completed.
02
Drugs
measles + mumps + rubella + varicella virus vaccine live
03
Conditions
measlesmumpsrubellavaricella (VZV)
Beyond the preview
Go deeper on NCT00092430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092430.